Innomedica OÜ
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Innomedica OÜ is conducting research in cardiovascular diseases, focusing on atherosclerotic cardiovascular disease and elevated lipoprotein(a). The studies are designed to assess whether new treatment approaches can reduce major heart-related events and improve long-term outcomes for people at higher cardiovascular risk.
- Evaluating a new therapy for lowering the risk of serious cardiovascular events
- Studying ASCVD and lipoprotein(a) as key targets in heart disease research
- Comparing treatment effects against placebo to understand protection from heart attack and related complications
This work reflects a strong focus on prevention and outcome improvement in cardiology, with attention to patients who may benefit from more effective risk reduction strategies.
Digestive System Diseases
The site is also involved in digestive system disease research, particularly for moderately to severely active ulcerative colitis. The trial activity in this area is aimed at improving disease control and helping more patients achieve clinical remission through new treatment options.
- Testing a potential therapy for ulcerative colitis
- Assessing whether treatment can improve signs and symptoms of active intestinal inflammation
- Supporting research into better ways to achieve and maintain remission in gastroenterology
These studies contribute to a broader effort to expand treatment choices for people living with chronic inflammatory bowel disease.
Skin and Connective Tissue Diseases
In the area of skin and connective tissue diseases, Innomedica OÜ is participating in research on psoriatic arthritis. The trials are focused on understanding long-term safety, tolerability, and effectiveness of treatment for adults with active disease.
- Monitoring long-term safety and tolerability in psoriatic arthritis
- Evaluating whether treatment can maintain symptom control over time
- Exploring outcomes that matter to patients with chronic inflammatory joint and skin disease
This research supports advances in rheumatology and dermatology, with a practical focus on sustained disease management and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Innomedica OÜ
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2) | Morphic Therapeutic Inc. | Phase II | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Morf-057 | 1 | Unknown | 2023-03-23 | 2023-03-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.